Drug Profile
Ubrogepant - AbbVie/Merck & Co
Alternative Names: MK-1602; UBRELVYLatest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer AbbVie
- Class Amides; Antimigraines; Cyclopentanes; Fluorine compounds; Piperidines; Pyridines; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 17 Nov 2023 Safety data from a phase III PRODROME trial in Migraine released by AbbVie
- 22 Apr 2023 Efficacy and adverse events data from a phase III PRODROME trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
- 22 Apr 2023 Efficacy data from a phase III PRODROME trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)